Xeris Ebit from 2010 to 2024
| XERS Stock | USD 3.58 0.03 0.83% |
EBIT | First Reported 2016-12-31 | Previous Quarter -6.3 M | Current Value -11.3 M | Quarterly Volatility 9.9 M |
Check Xeris Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Xeris Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 5 M, Depreciation And Amortization of 13.8 M or Interest Expense of 27.9 M, as well as many indicators such as Price To Sales Ratio of 1.88, Dividend Yield of 0.0 or Days Sales Outstanding of 154. Xeris financial statements analysis is a perfect complement when working with Xeris Pharmaceuticals Valuation or Volatility modules.
Xeris | Ebit |
Latest Xeris Pharmaceuticals' Ebit Growth Pattern
Below is the plot of the Ebit of Xeris Pharmaceuticals over the last few years. It is Xeris Pharmaceuticals' EBIT historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Xeris Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Ebit | 10 Years Trend |
|
Ebit |
| Timeline |
Xeris Ebit Regression Statistics
| Arithmetic Mean | (43,750,783) | |
| Coefficient Of Variation | (89.52) | |
| Mean Deviation | 32,366,678 | |
| Median | (26,506,000) | |
| Standard Deviation | 39,166,713 | |
| Sample Variance | 1534T | |
| Range | 109.1M | |
| R-Value | (0.63) | |
| Mean Square Error | 994T | |
| R-Squared | 0.40 | |
| Significance | 0.01 | |
| Slope | (5,527,212) | |
| Total Sum of Squares | 21476.4T |
Xeris Ebit History
Other Fundumenentals of Xeris Pharmaceuticals
About Xeris Pharmaceuticals Financial Statements
Xeris Pharmaceuticals shareholders use historical fundamental indicators, such as Ebit, to determine how well the company is positioned to perform in the future. Although Xeris Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Xeris Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Xeris Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| EBIT | -36.9 M | -38.7 M | |
| EBITDA | -23.7 M | -24.9 M | |
| Ebt Per Ebit | 1.44 | 0.90 | |
| Ebit Per Revenue | (0.27) | (0.28) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Xeris Stock Analysis
When running Xeris Pharmaceuticals' price analysis, check to measure Xeris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xeris Pharmaceuticals is operating at the current time. Most of Xeris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Xeris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xeris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Xeris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.